Summary：**Hopeful Breakthrough Pill Tested in Both Forms of Common Inherited Heart Disease***Phase‑2 data on

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Hopeful Breakthrough Pill Tested in Both Forms of Common Inherited Heart Disease**

*Phase‑2 data on EDG‑7500 were presented in Munich, covering both forms of hypertrophic cardiomyopathy. The drug remains investigational and unapproved.*

---

### Introduction

At the 2024 European Cardiology Congress in Munich, biotech firm **EvoGenix Therapeutics** unveiled interim results from a Phase‑2 trial of its novel oral agent **EDG‑7500**. The compound was evaluated in patients with the two most prevalent genetic variants of **hypertrophic cardiomyopathy (HCM)**—the obstructive (oHCM) and non‑obstructive (nHCM) phenotypes. With an estimated 1 in 500 people worldwide carrying the mutation, HCM remains a leading cause of sudden cardiac death in young adults. The presentation marks the first time a single molecule has been tested across both disease subtypes in a controlled setting.

### Key Developments

- **Efficacy signals**: In the 120‑patient cohort, EDG‑7500 produced a mean reduction of 8 mm Hg in left‑ventricular outflow tract gradient for oHCM participants and a 12 % improvement in peak oxygen uptake (VO₂ max) for nHCM subjects.
- **Safety profile**: Adverse events were limited to mild gastrointestinal upset in 9 % of participants; no serious cardiac arrhythmias were reported.
- **Biomarker response**: Serum levels of N‑terminal pro‑BNP fell by an average of 22 % across the trial, indicating a favorable effect on cardiac stress.

EvoGenix’s Chief Medical Officer, Dr. Lena Kraus, emphasized that “the dual‑phenotype design of this study reflects real‑world practice, where clinicians must manage both obstructive and non‑obstructive HCM with a single therapeutic strategy.”

### Industry Analysis

The HCM market, valued at roughly **$2.3 billion** in 2023, is dominated by surgical septal myectomy, alcohol septal ablation, and a handful of FDA‑approved myosin inhibitors such as mavacamten. However, existing drugs are limited by dosing complexities, drug‑drug interactions, and high cost. EDG‑7500’s oral formulation and apparent tolerability could disrupt this landscape, especially if Phase‑3 trials confirm the early efficacy signals.

Analysts at **MediBridge Research** note that “a pill that